A5042308431- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
- Vascular Malformations and Hemangiomas
- Image and Signal Denoising Methods
- Neuroblastoma Research and Treatments
- Image Retrieval and Classification Techniques
- Scheduling and Optimization Algorithms
- Advanced Data Compression Techniques
- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Optimization and Packing Problems
- Adenosine and Purinergic Signaling
- Simulation and Modeling Applications
- Advanced Manufacturing and Logistics Optimization
United States Food and Drug Administration
2023-2025
Center for Drug Evaluation and Research
2023
Guangdong Polytechnic Normal University
2011
Guangdong Technology College
2011
University of Illinois Urbana-Champaign
2010
On April 23, 2024, FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring BRAF fusion rearrangement, V600 mutation. Efficacy was evaluated in FIREFLY-1 (NCT04775485), single-arm, open-label, multicenter trial that enrolled 25 years pLGG an activating alteration who had received prior systemic therapy. The major efficacy outcome measure...
Abstract On April 5, 2022, FDA granted accelerated approval to alpelisib for the treatment of adult and pediatric patients 2 years age older with severe manifestations PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data (RWD) from EPIK-P1 (NCT04285723), a single-arm clinical study in or life-threatening PROS received as part an expanded access program (EAP) compassionate use. The primary endpoint confirmed radiologic response...
<div>Abstract<p>On April 5, 2022, FDA granted accelerated approval to alpelisib for the treatment of adult and pediatric patients 2 years age older with severe manifestations PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data (RWD) from EPIK-P1 (NCT04285723), a single-arm clinical study in or life-threatening PROS received as part an expanded access program (EAP) compassionate use. The primary endpoint confirmed...
<div>Abstract<p>On April 5, 2022, FDA granted accelerated approval to alpelisib for the treatment of adult and pediatric patients 2 years age older with severe manifestations PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data (RWD) from EPIK-P1 (NCT04285723), a single-arm clinical study in or life-threatening PROS received as part an expanded access program (EAP) compassionate use. The primary endpoint confirmed...
the core of intelligent manufacturing is Cyber-Physical system. In order to establish high frequency sampling system, massive data needed. It necessary study efficient transmission technology real-time data. Data compression through omitted part not or redundant, transfer and storage in finite strip width, space for more information a technical means. Embedded Wavelet coding (Embedded Zero tree Wavelet, EZW) based on transform multi-resolution analysis technology, extract tree, variable...